Dr. Dung T. Le, an expert from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses an exploratory study on using metformin and rapamycin as maintenance therapy for metastatic pancreatic adenocarcinoma patients. The study shows potential synergy in tumor suppression and exceptional survival rates. Topics covered include challenges in measuring clinical activity, PET scan utilization, biologic activity analysis, and identification of immune cell subsets.